Glut1 Deficiency Syndrome clinical trials
The registry lists 22 studies for Glut1 Deficiency Syndrome across more than 10 countries. 2 are recruiting or about to start. 14 of them are mainly about Glut1 Deficiency Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-07-01.
Get an email when these change. Save the Glut1 Deficiency Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Juan Pascual (4) · Vitaflo International, Ltd (3) · Ultragenyx Pharmaceutical Inc (3) · University of Texas Southwestern Medical Center (2) · Weill Medical College of Cornell University (2) · Oregon Health and Science University (1) · Radboud University Medical Center (1) · University of British Columbia (1)
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Nov 2026Early Check: Expanded Screening in Newborns · RTI International
- Jul 2027A Phase II Study With Exploratory Outcomes of Fucose Supplementation in GLUT1 Deficiency Syndrome · Oregon Health and Science University
Who these studies take
Of the 2 Glut1 Deficiency Syndrome studies recruiting now, 1 (50%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 2 (100%) | 2 (100%) |
| 30 | 2 (100%) | 2 (100%) |
| 40 | 2 (100%) | 2 (100%) |
| 50 | 2 (100%) | 2 (100%) |
| 65 | 2 (100%) | 2 (100%) |
| 75 | 2 (100%) | 2 (100%) |
| 85 | 1 (50%) | 1 (50%) |
Across all 22 studies, recruiting or not: 50% stop at 75 or younger and 50% at 65; 95% take children; 0% are for women only and 0% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 22 of 22. search them.
- Brain Metabolism Observed at 3 Tesla or 7 Tesla in Health and Metabolic DiseaseRecruitingNCT050857041 country
- A Phase II Study With Exploratory Outcomes of Fucose Supplementation in GLUT1 Deficiency SyndromeRecruitingNCT07432490Phase 21 country
- Early Check: Expanded Screening in NewbornsActive, not recruitingNCT036552231 country
- Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency SyndromeSuspendedNCT04137692Not applicable1 country
- Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DSCompletedNCT02014883Phase 21 country
- Baby Detect : Genomic Newborn ScreeningCompletedNCT056874741 country
- Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)CompletedNCT03181399Phase 21 country
- The Glucose Transporter Type I Deficiency (G1D) RegistryCompletedNCT020135831 country
- Evaluation of Keyo in Children With EpilepsyCompletedNCT02915211Not applicable1 country
- Evaluation of Krio in Children and Adults With EpilepsyWithdrawnNCT03202108Not applicable
- Evaluation of KetofloCompletedNCT04399954Not applicable1 country
- Treatment Development of Triheptanoin (G1D)CompletedNCT03041363Phase 11 country
- Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based TestCompletedNCT03722212Not applicable1 country
- Sodium Lactate Infusion in GLUT1DS PatientsCompletedNCT04112862Early Phase 11 country
- An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency SyndromeCompletedNCT02036853Phase 21 country
- Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)CompletedNCT01993186Phase 27 countries
- Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)TerminatedNCT02960217Phase 36 countries
- Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)TerminatedNCT02599961Phase 25 countries
- Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)CompletedNCT02018315Phase 11 country
- Post Study Continuation of C7 for G1DNo longer availableNCT020183021 country
- Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)WithdrawnNCT02021526Phase 1/21 country
- Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency SyndromeStatus unknownNCT02000960Phase 21 country